The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
S. Verstovsek
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Geron; Incyte; Lilly; Roche; S*Bio
J. Kiladjian
Consultant or Advisory Role - Novartis
R. J. Waltzman
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
V. Sandor
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
J. Lukawy
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
W. M. Garrett
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
K. Malek
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
R. M. Huber
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
A. M. Vannucchi
Consultant or Advisory Role - Novartis